Helicobacter pylori and chronic urticaria: The role of eradication

Carnevale, Paolo; Bierti, L.; Pigatto, P.D.M.; Masellis, P.; Franchis, R. de

doi:10.1016/s0016-5085(98)80340-5

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data pooled from 22 studies 25 , 63 , 180 –199 with 27 treatment arms resulted in an eradication rate of 86.2% ( n = 1289/1496); range 54–97% 193 , . 196 In four studies an ITT rate could not be determined 154 –156 , 200 and one report described a community study rather than a controlled clinical trial.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

Pipkin

Williamson

Wood

1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: One‐week triple therapies have been endorsed as the treatment regimens of choice for eradication of Helicobacter pylori infection. Those that include clarithromycin appear to be the most effective. Aim: To review reports of triple therapies that include clarithromycin. Methods: Reports were identified from the literature to May 1998. The variation between study designs prevents a formal meta‐analysis. A measure of the relative efficacies of regimens has, however, been gained by comparison and by pooling of intention‐to‐treat eradication rates. Results: One hundred and ninety‐two studies were identified which included 264 treatment arms of a 1‐week triple therapy composed of clarithromycin with amoxycillin or a nitroimidazole (metronidazole or tinidazole), and either ranitidine bismuth citrate or a proton pump inhibitor (omeprazole, lansoprazole or pantoprazole). From reports of these studies, an intention‐to‐treat H. pylori eradication rate could be determined from 210 treatment arms of 151 studies. Conclusions: There is little to choose between the efficacies of 1‐week clarithromycin‐based triple therapy eradication regimens. However, those comprising clarithromycin, a nitroimidazole and either ranitidine bismuth citrate or a high dose of omeprazole are, in general, the most effective. Against antibiotic‐resistant strains of H. pylori, regimens including ranitidine bismuth citrate may be more effective than those including a proton pump inhibitor.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Regimens including a single daily dose of O 20 mg 63 , 180 –187 , 190 , 192 , 198 gave a pooled eradication rate of 84.0% ( n = 510/607), regimens using O 20 mg b.d 25 , . 188 , 189 , 191 –193 , 195 –197 , 199 the somewhat higher rate of 87.9% ( n = 762/867).…”

Section: Resultsmentioning

confidence: 99%

One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

Pipkin

Williamson

Wood

1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In a study from Italy, 22 of 32 consecutive patients with chronic urticaria were infected with H pylori as determined by serologic examination and 13 C-UBT. 114 The infected patients were randomized to treatment for H pylori infection or to no treatment. It is unclear if randomization was blinded or if concealed allocation was used.…”

Section: Psoriasismentioning

confidence: 99%

Non–Gastrointestinal Tract Associations of Helicobacter pylori Infection

Leontiadis¹,

Sharma²,

Howden³

1999

Arch Intern Med

View full text Add to dashboard Cite

Helicobacter pylori infection is linked to conditions of the upper gastrointestinal tract, including peptic ulcer and gastric adenocarcinoma. It has also been associated with a wide variety of non-gastrointestinal tract conditions. However, the evidence in support of H. pylori infection as a cause of the non-gastrointestinal tract conditions is not widely understood. We reviewed the medical literature for publications and abstracts dealing with putative non-gastrointestinal tract associations of H. pylori infection. We appraised the level of evidence and applied it to an established set of 9 criteria for determining causation. We found that many studies examining a possible causal relationship have been uncontrolled or inadequately controlled. Studies have often failed to control for socioeconomic status. Studies of treating H. pylori infection in patients with these disorders have been poorly designed and inappropriately controlled, and therefore add little to the evidence base. Attention should be focused on appropriate testing for and treatment of H. pylori infection in patients with conditions that are of proven association, notably peptic ulcer disease.

show abstract

“…H pylori infection is seen in over 50% of patients with chronic idiopathic urticaria (151), usually in the absence of digestive symptoms, and with inconsistent improvement from 18% (151) to 80% in persons cured of their H pylori infection (152).…”

Section: Extragastroduodenal Diseasesmentioning

confidence: 99%

From Bench to Bedside to Bug: An Update of Clinically Relevant Advances in the Care of Persons withHelicobacter pyloriAssociated Diseases

Chiba

Thomson

Sinclair

2000

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

In-depth meetings of the XIth International Workshop on Gastroduodenal Pathology and Helicobacter pylori led to the presentation and discussion of extensive new data on H. pylori and its diseases. The mode of transmission of H. pylori remains unclear, and it remains unknown why only a small proportion of infected individuals develop duodenal or gastric ulcer disease and even fewer develop gastric cancer. The role of H. pylori eradication in persons with uninvestigated dyspepsia remains controversial. New clinical trials of H. pylori treatment show symptom relief and improvement in the quality of life of persons with functional dyspepsia, especially in those with ulcer-like or reflux-like dyspepsia. Clearly the move is toward symptom-based management of persons with dyspepsia, with fewer endoscopies being needed in the otherwise healthy young dyspeptic patients. It remains controversial whether eradicating H. pylori in duodenal ulcer or functional dyspepsia increases the risk of subsequent development of gastroesophageal reflux disease. The one-week proton pump inhibitor-based triple regimens remain the gold standard of H. pylori therapy, but some of the ranitidine bismuth citrate plus two antibiotic regimens also achieve an 80% H. pylori eradication rate on an intention-to-treat basis. While the urea breath test remains the noninvasive test of choice, interesting new data are available on the use of stool antigen testing to diagnose H. pylori infection. The number of H pylori-associated gastroduodenal diseases grows to include possible liver, vascular, immune and skin conditions.

show abstract

Helicobacter pylori and chronic urticaria: The role of eradication

Cited by 5 publications

References 0 publications

One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

Non–Gastrointestinal Tract Associations of Helicobacter pylori Infection

From Bench to Bedside to Bug: An Update of Clinically Relevant Advances in the Care of Persons withHelicobacter pyloriAssociated Diseases

Contact Info

Product

Resources

About